Safdar Lab Research Studies
Our team, led by Dr. Nasia Safdar, is focused on research aimed at reducing healthcare-associated infections (HAIs) and the rise of multi-drug resistant organisms (MDROs). We also are actively investigating the role of the microbiome in health and disease.
Research and Clinical Trials
Our clinical research program focuses on reducing the incidence of healthcare-associated infections (HAIs) and improving interventions for these infections with a particular emphasis on reducing the burden of multi-drug resistant infections (MDROs).
SAFE Study Now Recruiting
The SAFE Study is an influenza monitoring and prevention study. All ages may enroll.
Current Clinical Trials
SAFE Study
The SAFE Study is an influenza monitoring and prevention study. Learn More.
.
The goal of this research is to collect blood samples from participants across the country to better understand how the influenza (flu) virus changes across time and to develop vaccinations that do a better job of covering influenza virus strains from year to year.
SHIELD Study
The SHIELD Study is a COVID-19 prevention study. Learn More.
The goal of this research is to see if common antiseptic solutions are helpful in preventing COVID-19. Even with the success of COVID-19 vaccines, these solutions may prevent spread of multiple variants of SARS-CoV-2 (the virus that causes COVID-19)
Oral Vanc
The Oral Vanc study is a recurrent C. diff prevention study. Learn More.
.
This study’s goal is to study the use of vancomycin for preventing recurrent C. diff infection. Those who have been diagnosed with a C. diff infection in the past 6 months and will receive antibiotics for a reason other than C. diff may be eligible to join.
RECOVER
RECOVER focuses on treating recurrent C. diff in Solid Organ Transplant recipients. Learn More.
This study’s goal is to compare FMT treatment to oral vancomycin treatment for preventing recurrent C. diff infections in Solid Organ Transplant recipients. Those who have had an organ transplant and are currently receiving treatment for a recurrent C. diff infection may be eligible to join.
REBIOTIX
The Rebiotix study is a recurrent C. diff treatment study. Learn More.
.
This study’s goal to study FMT enema treatment for preventing recurrent C. diff. Those who are currently being treated with antibiotics for a recurrent C. diff infection may be eligible to join.
Latest Updates from the Lab
Welcome to the Safdar Research Lab Research Hub!
Welcome! This new website is the new outreach portal for Safdar Lab Research and Trials. Here you can find a list of active research studies that are seeking new participants and other info.
October 7, 2021- Click here to see all updates from the lab.
